N-Gene Inc., founded in 1997, is a clinical stage biopharmaceutical company developing a series of proprietary synthetic small molecules having a new therapeutic effect via stress response modulation (Nature Medicine 3: pp. 1150-1154. (1997) – Vígh et al.), and as such, representing a novel drug class. Lead compound of the Company, BGP-15 has been investigated extensively in preclinical and clinical studies and found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus.
N-Gene is a privately held shareholders’ company with private individuals as well, as professional investment funds on its registry. The Company is head-quartered in New York, NY (USA) and pursues research and development via its fully owned subsidiaries in Hungary and collaborators from virtually all over the world.